SourceCodester Drug Recommendation System 1.0 Drug Creation /Admin/add_drug.php sql injection
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.3 | $0-$5k | 1.77 |
Summary
A vulnerability has been found in SourceCodester Drug Recommendation System 1.0 and classified as problematic. The impacted element is an unknown function of the file /Admin/add_drug.php of the component Drug Creation. Performing a manipulation of the argument txtname/cmdtype/txtusage/txtsideeffect/cmdcontraindication results in sql injection. This vulnerability is cataloged as CVE-2026-105177. It is possible to initiate the attack remotely. Furthermore, there is an exploit available.
Details
A vulnerability, which was classified as problematic, was found in SourceCodester Drug Recommendation System 1.0. This affects an unknown part of the file /Admin/add_drug.php of the component Drug Creation. The manipulation of the argument txtname/cmdtype/txtusage/txtsideeffect/cmdcontraindication with an unknown input leads to a sql injection vulnerability. CWE is classifying the issue as CWE-89. The product constructs all or part of an SQL command using externally-influenced input from an upstream component, but it does not neutralize or incorrectly neutralizes special elements that could modify the intended SQL command when it is sent to a downstream component. This is going to have an impact on confidentiality, integrity, and availability.
This vulnerability is uniquely identified as CVE-2026-105177. The exploitability is told to be easy. It is possible to initiate the attack remotely. Additional levels of successful authentication are needed for exploitation. Technical details and a public exploit are known. MITRE ATT&CK project uses the attack technique T1505 for this issue.
It is declared as proof-of-concept. By approaching the search of inurl:Admin/add_drug.php it is possible to find vulnerable targets with Google Hacking.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Product
Vendor
Name
Version
License
Website
- Vendor: https://www.sourcecodester.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.7VulDB Meta Temp Score: 4.3
VulDB Base Score: 4.7
VulDB Temp Score: 4.3
VulDB Vector: 🔒
VulDB Reliability: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Sql injectionCWE: CWE-89 / CWE-74 / CWE-707
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Access: Public
Status: Proof-of-Concept
Google Hack: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
10/04/2026 Advisory disclosed10/04/2026 VulDB entry created
10/04/2026 VulDB entry last update
Sources
Vendor: sourcecodester.comStatus: Not defined
CVE: CVE-2026-105177 (🔒)
GCVE (CVE): GCVE-0-2026-105177
GCVE (VulDB): GCVE-100-413409
scip Labs: https://www.scip.ch/en/?labs.20161013
Entry
Created: 10/04/2026 10:55Changes: 10/04/2026 10:55 (53)
Complete: 🔍
Submitter: swj99557271
Cache ID: 216::103
Submit
Accepted
- Submit #970933: SourceCodester Drug Recommendation System 1.0 SQL Injection (by swj99557271)
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.